These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide. Crozier-Reabe KR; Phillips RS; Moran GR Biochemistry; 2008 Nov; 47(47):12420-33. PubMed ID: 18954092 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases. Shen H; Xu X; Bai Y; Wang X; Wu Y; Zhong J; Wu Q; Luo Y; Shang T; Shen R; Xi M; Sun H Eur J Med Chem; 2023 May; 251():115258. PubMed ID: 36917881 [TBL] [Abstract][Full Text] [Related]
25. First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists! Amin SA; Adhikari N; Jha T; Gayen S Bioorg Med Chem Lett; 2016 Dec; 26(23):5712-5718. PubMed ID: 27838184 [TBL] [Abstract][Full Text] [Related]
26. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371 [TBL] [Abstract][Full Text] [Related]
27. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Hutchinson JP; Rowland P; Taylor MRD; Christodoulou EM; Haslam C; Hobbs CI; Holmes DS; Homes P; Liddle J; Mole DJ; Uings I; Walker AL; Webster SP; Mowat CG; Chung CW Nat Commun; 2017 Jun; 8():15827. PubMed ID: 28604669 [TBL] [Abstract][Full Text] [Related]
28. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia. Réus GZ; Becker IRT; Scaini G; Petronilho F; Oses JP; Kaddurah-Daouk R; Ceretta LB; Zugno AI; Dal-Pizzol F; Quevedo J; Barichello T Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():55-63. PubMed ID: 29030243 [TBL] [Abstract][Full Text] [Related]
29. Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase. Kim HT; Na BK; Chung J; Kim S; Kwon SK; Cha H; Son J; Cho JM; Hwang KY Cell Chem Biol; 2018 Apr; 25(4):426-438.e4. PubMed ID: 29429898 [TBL] [Abstract][Full Text] [Related]
30. Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds. Jacobs KR; Guillemin GJ; Lovejoy DB SLAS Discov; 2018 Jul; 23(6):554-560. PubMed ID: 29420107 [TBL] [Abstract][Full Text] [Related]
31. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases. Boros FA; Bohár Z; Vécsei L Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576 [TBL] [Abstract][Full Text] [Related]
33. Absence of kynurenine 3-monooxygenase reduces mortality of acute viral myocarditis in mice. Kubo H; Hoshi M; Mouri A; Tashita C; Yamamoto Y; Nabeshima T; Saito K Immunol Lett; 2017 Jan; 181():94-100. PubMed ID: 27889626 [TBL] [Abstract][Full Text] [Related]
34. A novel role for kynurenine 3-monooxygenase in mitochondrial dynamics. Maddison DC; Alfonso-Núñez M; Swaih AM; Breda C; Campesan S; Allcock N; Straatman-Iwanowska A; Kyriacou CP; Giorgini F PLoS Genet; 2020 Nov; 16(11):e1009129. PubMed ID: 33170836 [TBL] [Abstract][Full Text] [Related]
35. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. Tan L; Yu JT; Tan L J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820 [TBL] [Abstract][Full Text] [Related]
36. Major Developments in the Design of Inhibitors along the Kynurenine Pathway. Jacobs KR; Castellano-Gonzalez G; Guillemin GJ; Lovejoy DB Curr Med Chem; 2017; 24(23):2471-2495. PubMed ID: 28464785 [TBL] [Abstract][Full Text] [Related]
37. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO). Winkler D; Beconi M; Toledo-Sherman LM; Prime M; Ebneth A; Dominguez C; Muñoz-Sanjuan I J Biomol Screen; 2013 Sep; 18(8):879-89. PubMed ID: 23690293 [TBL] [Abstract][Full Text] [Related]
38. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease. Toledo-Sherman LM; Prime ME; Mrzljak L; Beconi MG; Beresford A; Brookfield FA; Brown CJ; Cardaun I; Courtney SM; Dijkman U; Hamelin-Flegg E; Johnson PD; Kempf V; Lyons K; Matthews K; Mitchell WL; O'Connell C; Pena P; Powell K; Rassoulpour A; Reed L; Reindl W; Selvaratnam S; Friley WW; Weddell DA; Went NE; Wheelan P; Winkler C; Winkler D; Wityak J; Yarnold CJ; Yates D; Munoz-Sanjuan I; Dominguez C J Med Chem; 2015 Feb; 58(3):1159-83. PubMed ID: 25590515 [TBL] [Abstract][Full Text] [Related]